Company news
Abeona Therapeutics Inc. news in 2025
Abeona Therapeutics Inc.'s news releases, calls and decks from 2025, newest first.
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
December 14, 2025
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
December 10, 2025
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
December 7, 2025
Abeona Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
November 13, 2025
Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
November 11, 2025
Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
November 6, 2025
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
October 29, 2025
Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
October 19, 2025
Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program
October 12, 2025
Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy
October 7, 2025
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
August 28, 2025
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
August 13, 2025
AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients
July 29, 2025
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
July 14, 2025
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
July 1, 2025
Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
June 30, 2025
Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index
June 29, 2025
Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa
June 23, 2025
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference
May 29, 2025
ABEO: Sells Priority Review Voucher for $155 Million…
May 19, 2025
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
May 14, 2025
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
May 14, 2025
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
May 13, 2025
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder
May 13, 2025
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million
May 11, 2025
ABEO: Zevaskyn™ Approved by FDA; Raising Valuation to $11…
April 30, 2025
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
April 28, 2025
Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans
March 19, 2025
Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference
March 3, 2025
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 3, 2025
Calls in 2025
Decks in 2025
- Corporate Update (April 2025)
Corporate update · 22 slides · Apr 29, 2025